SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

ABCL688

ABCL·AbCellera Biologics Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / IND-enabling
Time to market
Not stated
Why 2/10
No hard dated catalyst is scheduled for ABCL688 in the next ~12 months. The program entered IND-enabling studies in mid-2025, but as of the Q3 2026 earnings call (November 9, 2026), AbCellera disclosed it had shelved further development of a separate antibody candidate (likely ABCL688) to focus resources on ABCL635. With no active clinical trial, no PDUFA date, and no publicly disclosed next catalyst date, the impact score is low.
Actionable Insight NEUTRAL

ABCL688 appears to have been deprioritized or shelved as of AbCellera's Q3 2026 update. The company is focusing its resources on advancing ABCL635 (hot flash antibody) into Phase 3 in 2027. Investors should watch for any mention of ABCL688 in future earnings calls or corporate presentations to see if development resumes, but for now the program appears inactive.

Price Chart

Loading chart...

Executive Summary

ABCL688 is an early-stage, preclinical antibody candidate from AbCellera Biologics (NASDAQ: ABCL). The drug entered IND-enabling studies in mid-2025, according to the company's Q2 2025 earnings call. However, based on AbCellera's Q3 2026 earnings update (November 9, 2026), management indicated it was shelving further development of a separate antibody candidate to focus resources on its lead program ABCL635 (menopausal hot flashes). No clinical trials have been initiated for ABCL688, no specific target or indication has been publicly disclosed, and no upcoming catalysts are scheduled. The program appears to have been deprioritized.

How It Works

ABCL688 is an investigational antibody drug being developed by AbCellera. The specific molecular target and therapeutic indication have not been publicly disclosed by the company. It is part of AbCellera's internal pipeline of proprietary antibody programs.

Trial Status

ABCL688 entered IND-enabling studies in 2025, as disclosed in AbCellera's Q2 2025 earnings call. As of Q3 2026, the company appears to have shelved this program to focus on its lead asset ABCL635. No clinical trial has been initiated for ABCL688, and no active ClinicalTrials.gov record exists for this candidate.

The Two-Sided Case

▲ Bull Case3
AbCellera has a strong antibody discovery platform and a growing cash position (raised $200M after ABCL635 Phase 2 data), which could allow it to revisit ABCL688 later.
The program reached IND-enabling studies, suggesting sufficient preclinical proof-of-concept to justify regulatory filing preparation.
AbCellera has multiple partnered programs generating revenue ($10.6M in Q3 2026) that could support pipeline expansion.
▼ Bear Case4
ABCL688 appears to have been shelved as of Q3 2026, with no active development or clinical trials underway.
The specific target, mechanism, and indication have never been publicly disclosed, making it impossible to assess competitive positioning or market opportunity.
AbCellera is prioritizing ABCL635 (hot flashes) and ABCL575 (atopic dermatitis), leaving ABCL688 as a lower-priority preclinical asset with no near-term catalysts.
The company reported a Q3 2026 net loss of $40.8 million, and focusing resources on fewer programs means ABCL688 may not return to active development.

Upcoming Catalysts

  • No upcoming catalysts identified for ABCL688. The program has been shelved with no publicly disclosed next steps or timeline.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbCellera Biologics Inc. 8-K ABCL ·Originating report

Sources · 4

Hover a chip for the title
1 aol.com2 msn.com3 rttnews.com4 247wallst.com